Person:
ATASOY, BESTE MELEK

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

ATASOY

First Name

BESTE MELEK

Name

Search Results

Now showing 1 - 10 of 37
  • Publication
    The effect of magnesium and vitamin E pre-treatments on irradiation-induced oxidative injury of cardiac and pulmonary tissues in rats: a randomized experimental study
    (TURKISH SOC CARDIOLOGY, 2012) ATASOY, BESTE MELEK; Atasoy, Beste M.; Ozgen, Zerrin; Bostanci, Korkut; Yuksel, Meral; Ozen, Zeynep; Ibrahimov, Roman; Abacioglu, Ufuk
    Objective: The aim of this study was to investigate the effect of pre-treatment with the free radical scavenging molecules, magnesium and vitamin E, on lipid peroxidation to limit radiation-induced heart and lung injury. Methods: Female Sprague-Dawley rats were divided into 4 groups by a simple randomization method as saline-treated control (n=4), saline-treated irradiated (IR; n=6), magnesium sulphate-treated irradiation (IR) (Mg+IR; n=6) and vitamin E-treated IR (vit E+IR; n=6), respectively. The animals were given either saline, Mg (600mg/kg/day) or vit E (100 mg/kg/day) intraperitoneally for five days prior to irradiation. Twelve hours after the fifth injection, animals in irradiation groups were irradiated to 20 Gy using 6 MV photons in linear accelerator. Twenty-four hours later cardiac and lung tissue samples were obtained for determination of myeloperoxidase activity (MPO), malondialdehyde (MDA) levels, and luminol and lucigenin levels measured by chemiluminescence (CL) methods. Results: No significant changes were observed between cardiac and pulmonary MDA and CL results of the experimental groups. However, cardiac and pulmonary MPO activities in the saline-treated IR group were increased as compared to control group (p<0.05 for all), while in the Mg-pretreated and vit E pretreated groups neutrophil infiltration was reduced, reaching to statistical significance only in the Mg-pretreated group (p<0.05). Conclusion: Prophylactic use of magnesium sulfate has limited the infiltration of neutrophils to both the cardiac and pulmonary tissues at the early 24 h of irradiation. However, how limiting neutrophils as the sources of free radicals and inflammatory mediators would alter oxidative stress of heart and lung tissues in the long-term is not clear yet. (Anadolu Kardiyol Derg 2012; 12: 508-14)
  • PublicationOpen Access
    Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
    (OXFORD UNIV PRESS, 2011-01) ATASOY, BESTE MELEK; Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.
    Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
  • Publication
    Quali̇ty of li̇fe evaluation wi̇th turki̇sh version of eortc c30 and br 23 questionnaires in breast cancer patients following radiotherapy
    (2014-09-30) ÖZGEN, ZERRİN; ATASOY, BESTE MELEK; KUŞCU, MEHMET KEMAL; Özgen Z., Atasoy B. M., Karaüç G., Kuşcu M. K.
  • PublicationOpen Access
    Clinical Outcomes of Rectal Squamous Cell Carcinomas Treated with Chemoradiotherapy with or Without Surgery: A Rare Cancer Network Study.
    (ELSEVIER SCIENCE INC, 2018-11) ATASOY, BESTE MELEK; De Bari, B.; Aloi, D.; Lemanski, C.; Hallemeier, C. L.; Touboul, E.; Qi, S.; Christie, D.; Vees, H.; Shulman, K.; Atasoy, B. M.; Sefik, I.; Micke, O.; Vernat, S. Servagi; Khanfir, K.
  • Publication
    Students Meeting with Caregivers of Cancer Patient: Results of an Experience-Based Learning Project
    (SPRINGER, 2012) ATASOY, BESTE MELEK; Atasoy, Beste M.; Sarikaya, Ozlem; Kuscu, M. Kemal; Yondem, Merve; Buyukkara, Elif; Eken, E. Gokcen; Kahyaoglu, Figen
    The communication between medical students and cancer caregivers, and the problems they have experienced as well as the outcomes for their professional development before starting clinical practice was assessed in the context of a student research project. Data were collected by questionnaires or by 20 to 40-min long interviews with cancer caregivers. Their communications with physicians, hearing the bad news, and health service satisfaction were questioned. Therefore, the caregivers trusted the professional approach of their physician. However, they expected more empathic communication in the process of diagnosis and therapy. Development of empathy and trust-based communication between patients and physicians and enhancement of the quality of devoted time to cancer patients and caregivers may have an effect on the course of disease. Interviewer students mentioned that they developed communication skills about difficult clinical tasks and in delivering bad news face to face to cancer caregivers before starting their clinical education.
  • Publication
    Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
    (SPRINGER, 2011) ATASOY, BESTE MELEK; Abacioglu, Ufuk; Caglar, Hale B.; Yumuk, Perran F.; Akgun, Zuleyha; Atasoy, Beste M.; Sengoz, Meric
    The current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical resection plus radiotherapy and concurrent temozolomide, then adjuvant temozolomide for 6 months. This has been shown to provide survival benefits; however, the prognosis for these patients remains poor, and most relapse. The objective of this prospective Phase II study was to evaluate the efficacy and tolerability of protracted, dose-dense temozolomide therapy (100 mg/m(2) for 21 consecutive days of a 28-day cycle) in patients with recurrent glioblastoma or grade 3 gliomas who had previously received standard therapy. Of the 25 patients included (median age 50 years), 20 were evaluable for radiologic response. Two patients had partial responses and 10 had stable disease (60% overall clinical benefit); 8 patients (40%) progressed after the first treatment cycle. Five patients were not assessed for radiologic response due to early clinical progression but were included in the progression-free survival (PFS) and overall survival (OS) analyses. The median follow-up time was 7 months (range, 1-14 months). The median PFS was 3 months (95% confidence interval, CI, 1.8-4.2) and the median OS was 7 months (95% CI 5.1-8.9). The 6-month PFS rate (primary endpoint) was 17.3% (95% CI 1.7-32.2) and the 1-year OS rate was 12% (95% CI -1-25). This regimen was well tolerated. The most frequent adverse event was lymphopenia (grade 3-4 in 20 patients); no opportunistic infections were reported. Treatment was discontinued due to toxicity in 2 patients (grade 4 hepatic toxicity and thrombocytopenia). These data suggest that protracted, dose-dense temozolomide had modest activity with manageable toxicity in patients with recurrent high-grade glioma previously treated with temozolomide.
  • Publication
    Farkli radyoterapi̇ tekni̇kleri̇n üst batın yerleşmli̇ tümörleri̇n tedavi̇si̇nde dozi̇metri̇k açıdan karşılaştırılması
    (2014-04-23) ÖZGEN, ZERRİN; ADLI, MUSTAFA; ATASOY, BESTE MELEK; Dağlı A., Özgen Z., Güneyli O., Adlı M., Karaüç G., Atasoy B. M.
  • Publication
    The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy
    (SPRINGER, 2012) ATASOY, BESTE MELEK; Atasoy, Beste M.; Yonal, Oya; Demirel, Birsen; Dane, Faysal; Yilmaz, Yusuf; Kalayci, Cem; Abacioglu, Ufuk; Imeryuz, Nese
    To investigate the impact of early insertion of percutaneous endoscopic gastrostomy-tube on nutritional status and completeness of concurrent chemotherapy in locally advanced head and neck cancer patients treated with chemoradiotherapy. Twenty-three patients were enrolled into this prospective study. Gastrostomy-tube was inserted in patients before the initiation of chemoradiotherapy. There was not any significant change in nutritional parameters of patients that used their tube during treatment. Despite the grade 3 mucositis, the planned concurrent chemotherapy could be given in 70% of the patients. However, nine patients had weak compliance and their body weight (P = 0.01) and body mass index (P = 0.01) deteriorated in the first 4 weeks of chemoradiotherapy. The completeness of concurrent chemo-rate was 44% in these patients. Toxicity, requiring aggressive supportive care, may limit the chemotherapy part of curative concomitant chemoradiotherapy. By providing adequate enteral nutrition the insertion of gastrostomy-tube can increase the completeness rate of concurrent chemotherapy.
  • Publication
    Grad III anaplasti̇k gli̇al tümör tanili hastalarda radyoterapi̇yle eş zamanli adjuvan temozolami̇d sonuçlari tek merkez deneyi̇mi̇
    (2014-05-23) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; Sahibov E., Atasoy B. M., Şeker A., Özgen Z., Dane F., Ziyal M. İ., Abacıoğu U.
  • Publication
    Design and characterization of polycaprolactone-gelatin-graphene oxide scaffolds for drug influence on glioblastoma cells
    (PERGAMON-ELSEVIER SCIENCE LTD, 2019) ATASOY, BESTE MELEK; Unal, Semra; Arslan, Sema; Gokce, Tilbe; Atasoy, Beste Melek; Karademir, Betul; Oktar, Faik Nuzhet; Gunduz, Oguzhan
    Three-dimensional (3D) scaffolds that mimic in vivo tumor microenvironments can be used to study tumor response to anticancer treatments, since most preclinical combination treatment strategy for anti-glioma were evaluated with traditional 2D cell culture. In this research, the nanofiber scaffolds of polycaprolactone (PCL) containing gelatin (Gel) nano/microparticles coated with different concentrations of graphene oxide (GO) and were successfully produced by combining electrospinning and electrospraying techniques. Scanning electron microscope (SEM), Fourier-transform infrared (FT-IR) spectroscopy and mechanical testing were used to characterize the structure and properties of the composites. The results show that gelatin and graphene particles can be well dispersed in the polycaprolactone nanofiber matrix by using the combination technique of electrospinning and electrospraying. The presence of 1 wt% graphene oxide increased mechanical strength of PCL/Gel scaffold and was found to be well consistent with the drug treatments (temozolomide and bortezomib) and radiotherapy by not showing additional toxicity.